Researchers have investigated the prevalence of “off-label” anti-asthma prescriptions in relation to clinical symptoms of asthma control in children. A UK-wide database of structured asthma review consultations was used, and included data from 17163 children aged </=16 years. An off-label prescription was identified as a formulation not licensed for use in children, not licensed for use in a particular age group, or with a specific dosage not licensed for use. A UK-wide database of structured asthma review consultations was used to investigate the prevalence of ‘off-label’ anti-asthma prescriptions in relationship to clinical symptoms of asthma control. Of the 17163 children, 1050 (6.1%) received an off-label prescription, 325 (1.9%) received drugs not licensed for their age group, and 767 (4.5%) received drugs at a higher than recommended dosage. The researchers reported that compared to children receiving medications within the licensed indications or doses, those who received off-label prescriptions reported statistically significantly more nighttime symptoms, daytime symptoms, symptoms during activity and increased used of daily short-acting beta2 agonists. The researchers conclude that off-label prescribing by GPs is increasing, and decisions should assess the risks and benefits.